MDM2 and cancer: The majority of TP53-related drug development efforts have been directed towards designing therapies to exploit cancer-specific vulnerabilities associated with dysregulation of TP53, such as del17p, TP53 mutations, TP53 promoter methylation, and MDM2 overexpression [70,116].